Bladder cancer is second among the most common urothelial malignancy and one of the most expensive in terms of treatment. Localized bladder cancer is classified into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). First line approach for treatment of NMIBC is transurethral resection of bladder tumor (TURBT) followed by intravesical instillation of immuno/chemotherapeutic agents to prevent or delay recurrence or progression. Historically intravesical Bacillus Calmette Geurin (BCG) instillation has been a mainstay of therapy for NMIBC post-TURBT. Commonly followed drug delivery is intravesical instillation that maximizes exposure of the drug to the lesion and minimizes systemic side effects. Gemcitabine used in bladder cancer due to its pharmacological properties making it appropriate for intravesical instillation. Limitations of intravesical instillation is low bladder permeability leading to decreased drug concentration in bladder tissues and frequent urination causing drug wash out or dilution reducing the effect of treatment. Effective intravesical therapy depends on the penetration of the drug into the tumor. TAR200 is a novel drug delivery system that facilitates sustained release of continuous low dose gemcitabine over an indwelling period providing a uniform concentration of drug after each voiding cycle and exposure of drug to the bladder tumor. There are completed and ongoing clinical trials to evaluate the efficacy of TAR200 alone or in combination with other chemotherapeutic agents in NMIBC and MIBC. FDA has granted breakthrough therapy designation (BTD) for TAR-200 in December 2023. This review highlights the potential of TAR-200 and clinical trials that improve bladder cancer treatment outcome.
AvritscherEBCooksleyCDGrossmanHB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology2006; 68(3): 549–553.
2.
BottemanMFPashosCLRedaelliA, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics2003; 21: 1315–1330.
3.
AntoniSFerlayJSoerjomataramI, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol2017; 71(1): 96–108.
4.
SungHFerlayJSiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71(3): 209–249.
5.
GraysonM. Bladder cancer. Nature2017; 551: S33.
6.
KamatAMHahnNMEfstathiouJA, et al. Bladder cancer. Lancet2016; 388: 2796–2810.
7.
CambierSSylvesterRJColletteL, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol2016; 69(1): 60–69.
8.
ShelleyMDWiltTJCourtJ, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int2004; 93(4): 485–490.
9.
BöhleAJochamDBockPR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol2003; 169(1): 90–95.
10.
ChangSSBoorjianSAChouR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol2016; 196(4): 1021–1029.
11.
GildPNguyenDDFletcherSA, et al. Contemporary survival rates for muscle-invasive bladder cancer treated with definitive or non-definitive therapy. Clin Genitourin Cancer2019;17(3):e488–e493.
12.
WitjesJABruinsHMCathomasR, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol2021; 79(1): 82–104.
13.
International Collaboration of Trialists. Medical Research Council Advanced Bladder Cancer Working Party. European Organisation for Research. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol2011; 29: 2171–2177.
14.
GrossmanHBNataleRBTangenCM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003; 349: 859–866.
15.
AzizAMayMBurgerM, et al. Prediction of 90-day mortality after radical cystectomy for bladdercancer in a prospective European multicentercohort. Eur Urol2014; 66(1): 156–163.
16.
HautmannREde PetriconiRCVolkmerBG. Les-sons learned from 1,000 neobladders: the 90-daycomplication rate. J Urol2010; 184(3): 990–994.
17.
HamidARAHRidwanFRParikesitD, et al. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol2020; 20: 158.
18.
GalskyMDPalSKChowdhuryS, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer2015; 121: 2586–2593.
19.
YuhBERuelNWilsonTG, et al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol2013; 189: 1682–1686.
20.
CattelLAiroldiMDelprinoL, et al. Pharmacokinetic evaluation of gemcitabine and 20,20 -difluorodeoxycytidine-50 -triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol2006; 17: v142–v147.
21.
LiRLiYSongJ, et al. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial. BMC Urol2020; 20: 97.
22.
Patel HitenDPatel SunilHBlanco-MartinezE, et al. Four versus 3 cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: implications for pathological response and survival. J Urol2022; 207: 77–85.
23.
RoseTLDealAMLadoireS, et al. Patterns of bladder preservation therapy utilization for muscle-invasive bladder cancer. Bladder Cancer2016; 2: 405–413.
24.
PatelVGOhWKGalskyMD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin2020; 70: 404–423.
25.
MaffezziniMCampodonicoFCanepaG, et al. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta−T1, G1−G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol2007; 51: 956–961.
26.
GardmarkTCarringerMBeckmanE, et al. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology2005; 66: 527–530.
27.
PanSZhanYChenX, et al. Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices. Front Oncol2019; 9: 613.
28.
YangZLiCFanZ, et al. Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells. Eur Urol2017; 71(1): 8–12.
29.
CarattinoMDPrakasamHSRuizWG, et al. Bladder filling and voiding affect umbrella cell tight junction organization and function. Am J Physiol Renal Physiol2013; 305(8): F1158–F1168.
30.
KreftMEHudoklinSJezernikK, et al. Formation and maintenance of blood–urine barrier in urothelium. Protoplasma2010; 246: 3–14.
31.
LasičEVišnjarTKreftME. Properties of the urothelium that establish the blood–urine barrier and their implications for drug delivery. Rev Physiol Biochem Pharmacol2015; 56: 1–29.
32.
JanssenDAvan WijkXMJansenKC, et al. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J Urol2013; 189(1): 336–342.
33.
KlinglerCH. Glycosaminoglycans: how much do we know about their role in the bladder?Urol J2016; 83: 11–14.
34.
LillyJDParsonsCL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet1990; 171: 493.
35.
WangSJinSShuQ, et al. Strategies to get drugs across bladder penetrating barriers for improving bladder cancer therapy. Pharmaceutics2021; 13(2): 166.
36.
JoiceGABivalacquaTJKatesM. Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nat Rev Urol2019; 16(10): 599–612.
37.
MerrillLGonzalezEJGirardBM, et al. Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat Rev Urol2016; 13(4): 193–204.
38.
ChouRSelphSBuckleyDI, et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol2017; 197(5): 1189–1199.
39.
MartiniASfakianosJPRenstrom-KoskelaL, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int2020; 125(2): 270–275.
40.
GrayPJFedewaSAShipleyWU, et al. Use ofpotentially curative therapies for muscle-invasive bladder cancer in the United States: results from Figure 5. Swimmer plot of tumor responses. Eur Urol2013; 63(5): 823–829.
41.
JohnJBVarugheseMACooperN, et al. Treatment allocation and survival in patients diagnosed with non-metastatic muscle-invasive bladder cancer: an analysis of a national patient cohort in England. Eur Urol Focus2021; 7(2): 359–365.
42.
WestergrenDOGardmarkTLindhagenL, et al. A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014. J Urol2019; 202(5): 905–912.
43.
LeeHCimacMJ. Design of an elastomeric tubular osmotic pump for intravesical delivery of lidocaine to the bladder. J Med Dev2012; 6(1): 017533.
44.
NickelJCJainPShoreN, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Translat Med2012; 4(143): 143ra100.
45.
DaneshmandSBrummelhuisISPoharKS, et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. In Urologic oncology: seminars and original investigations2022 (Vol. 40, No. 7, pp. 344–e1). Elsevier.
46.
GrimbergDCShahAInmanBA. Overview of taris GemRIS, a novel drug delivery system for bladder cancer. Eur Urol Focus2020; 6(4): 620–622.
47.
DouglassLSchoenbergM. The future of intra-vesical drug delivery for non-muscle invasive bladder cancer. Bladd Cancer2016; 2(3): 285–292.
48.
GiesingDHReynoldsDAgarwalV, et al. Abstract LB-122: Significant cytotoxic and immumomodulatory effects of continuous low dose intravesical gemcitabine in rodent bladder tumor models. Cancer Res2018; 78(13_Supplement): LB-122.
49.
P van ValenbergFJvan der HeijdenAGCutieCJ, et al. The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American urological association-defined intermediate-risk non-muscle-invasive bladder cancer patients: a phase 1b study. Eur Urol Open Sci2024; 62: 8–15.
50.
TysonMDMorrisDPalouJ, et al. Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study. J Urol2023; 209(5): 890–900.
